Commentary: Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model by Stephen T. Abedon
GENERAL COMMENTARY
published: 10 August 2016
doi: 10.3389/fmicb.2016.01251
Frontiers in Microbiology | www.frontiersin.org 1 August 2016 | Volume 7 | Article 1251
Edited by:
Joshua D. Nosanchuk,
Albert Einstein College of Medicine,
USA
Reviewed by:
Philippe Georgel,
University of Strasbourg, France
Victor Krylov,
I. I. Mechikov Institute for Vaccines
and Sera, Russia
*Correspondence:
Stephen T. Abedon
abedon.1@osu.edu
Specialty section:
This article was submitted to
Antimicrobials, Resistance and
Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 20 June 2016
Accepted: 28 July 2016
Published: 10 August 2016
Citation:
Abedon ST (2016) Commentary:
Phage Therapy of Staphylococcal
Chronic Osteomyelitis in Experimental
Animal Model.
Front. Microbiol. 7:1251.
doi: 10.3389/fmicb.2016.01251
Commentary: Phage Therapy of
Staphylococcal Chronic
Osteomyelitis in Experimental Animal
Model
Stephen T. Abedon*
Department of Microbiology, The Ohio State University, Mansfield, Ohio, USA
Keywords: phage therapy, chronic infection, antibacterial agents, bacteriophages, staphylococcal infections,
animal models
A commentary on
Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model
by Kishor, C., Mishra, R. R., Saraf, S. K., Kumar, M., Srivastav, A. K., and Nath, G. (2016). Indian J.
Med. Res. 143, 87–94. doi: 10.4103/0971-5916.178615
Phage therapy—the use of bacterial viruses as equivalents of antibacterial “drugs”—has been
practiced for nearly 100 years. Much, particularly since the 1940s, has taken place in the former
Soviet Union. Nevertheless, interest in phage therapy in Western countries has been steadily
building since the 1980s. Much of this interest has been in response to growing concerns over
antibiotic resistance, though there are concerns, as well, over antibiotic side effects (Langdon et al.,
2016). Phage therapy inmany cases has been used as ameans of treating chronic bacterial infections
which may be tolerant to antibiotic treatment rather than necessarily also genetically resistant. This
antibiotic tolerance is thought to occur predominantly as a consequence of bacterial growth within
biofilms (Olsen, 2015). In practice, however, what is going on is that phage therapy has been used
to treat bacterial infections against which antibiotics, often following months or years of treatment,
have not been successful (e.g., Rhoads et al., 2009; Wright et al., 2009; Miedzybrodzki et al., 2012).
Despite this clinical aspect of phage therapy, pre-clinical studies have not tended to focus
experimentally on chronic bacterial infections. There have been exceptions, however, particularly
in which a fair amount of time has elapsed between bacterial challenge and start of phage treatment
(Table 1). Here I focus on the recent study of Kishor et al. (2016), which employs the longest delay
of which I am aware, in an animal model, between bacterial challenge and phage application.
Kishor et al. (2016) present a rabbit model of chronic osteomyelitis caused by a
methicillin-resistant isolate of Staphylococcus aureus. Two rabbits were used to test phage cocktail
safety (intraperitoneal delivery of ∼1011 plaque-forming units), four served as untreated controls,
12 were treated with phages after ∼3 weeks, and another four were treated with phages after 6
weeks. Cocktails consisted of seven phages and a total of four doses were applied, 2 days between
each. Wounds were prepared thusly (p. 89): “. . . a 2 cm long incision was made at the lateral aspect
of distal end of femur and metaphysial area was exposed. With the help of a hand drill, a 5mm
diameter unicortical defect was created. . . ” Following bacterial inoculation, “The incised area was
covered by sterile bandages with one stitch at middle of open area.” Phage treatment by injection
into the infected area, with either 3- and 6-week delays, resulted in negative cultures in 15 cases.
The 16th was sacrificed for study prior to completion of phage administration.
I have a few minor criticisms of the study, which the authors note is “preliminary.” First,
it is difficult to tell just how many bacteria were applied. Second, all control rabbits were
sacrificed during week 6, meaning that there were no no-treatment controls for the 6-week-delay
experiments. Lastly is the notion of “lysis of bacteria from outside,” which I interpret as reference
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TABLE 1 | Animal models of human phage therapy with treatment delays exceeding 24h.a
Organism(s)
treated
Delay
before
treatmentb
Challenge Consequence Treatment Resultsc References
Escherichia coli 168 h Force-fed axenic mice
with 5 × 107 CFU
Intestinal
colonization
105 PFU/ml in drinking
water
∼108 CFU/ml reduced to
∼104 CFU/ml in feces
Chibani-Chennoufi
et al., 2004
Escherichia coli
O157:H7
48 h Force-fed mice with
109 CFU
Intestinal
colonization
Force fed 108 PFU, 1
dose, or 1010 PFU, 1
dose or “daily”
<103 vs. <102 CFU/g in
feces for control (etc.) vs.
“daily” treatment, around
day 8
Tanji et al., 2005
Mycobacterium
avium
168 h IV 3 × 107 CFU to mice Continuing
replication
IV 8 × 109 PFU or 4 ×
107 phage-infected M.
smegmatis in 100µl, 1
or 2 doses
∼0.5-log fewer CFU in
spleen for phage-infected
M. smegmatis, day 14, no
reduction for phage only
Danelishvili et al.,
2006
Staphylococcus
aureus
96 h Subcutaneous 108 or
109 CFU/mouse
Abscess
development
Subcutaneous 109
PFUd in 200µl, 1 or 4
doses
∼108 vs. ∼106 or ∼104
CFU per abscess for control
vs. treatments
Capparelli et al.,
2007
Staphylococcus
aureus
240 h IV 5 × 106 CFU to mice Non-lethal
systemic infection
109 PFU in 200µle ∼104 CFU vs. 0 in various
organs, day 20
Capparelli et al.,
2007
Pseudomonas
aeruginosa
96, 240 hf 108 CFU/ml in mouse
drinking waterg
Gut-derived
septicemia
1010 PFU in 100µl
orally administered
0, 10, and 66.7% 20-day
survival for no, 240, and
96-h treatments
Watanabe et al.,
2007
Salmonella
enterica
48, 336 h IV 106 or 105 CFU,
respectively, to mice
Sublethal systemic
infection
IV 107 PFU in 100µl ∼104 CFU reduced to 0 in
various organs
Capparelli et al.,
2010
Acinetobacter
baumannii,
Pseudomonas
aeruginosa,
Staphylococcus
aureus
96 h Mouse wounds
injected with 100µl of
organisms of one type
Infected wound
(diabetes mellitus
model)
108–109 PFU
presumably topical
following one or more
debridements, >10
doses
∼105 vs. ∼102 CFU/swab,
day 8, control vs. treatment
(S. aureus)h
Mendes et al., 2013
Mycobacterium
ulcerans
792 h Subcutaneous 3 × 105
CFU into mouse
footpad
Footpad swelling
with continuing
replication
Subcutaneous 108
PFU into mouse
footpad
∼3 × 105 vs. ∼3 × 103
CFU/footpad, day 68,
control vs. treatment
Trigo et al., 2013
Staphylococcus
aureus (MRSA)
96 h Intranasal 106
CFU/mouse
Nare potentially
transient
colonization
Intranasal 50µl of 107
PFU/ml, 2 doses
∼105.5 vs. ∼101 CFU/g,
day 11, control vs.
treatment
Chhibber et al.,
2014
Staphylococcus
aureus
168 h Sinus inoculation of
sheep
Sinusitis model Sinus inoculation of
100ml of 2 × 108
PFU/ml, 5 doses
∼80% reduction in biofilm
biomass, control vs.
treatment
Drilling et al., 2014
Acinetobacter
baumannii
(multi-drug
resistant)
48 h 108 CFU inoculated
into wound of diabetic
rats
Abscess
development
400µl of 3 × 109/ml
PFU sprayed onto
debrided wound
∼109 vs. 0 CFU, day 8,
control vs. treatment
Shivaswamy et al.,
2015
Klebsiella
pneumoniae
48, 72 h Intranasal 104
CFU/mouse
Lobar pneumonia IP, liposome-entrapped
phagesi
∼105 vs. ∼103 vs. 0 CFU,
day 5, control vs. 72-h delay
vs. 48-h delayj
Singla et al., 2015
Staphylococcus
aureus (MRSA)
504,
1008 hk
Intramedullary injection
of rabbits with
uncertain number
(≤5× 106) CFU
Chronic
osteomyelitis
Intralesional injection of
5 × 1011 PFU, 4 doses
Cure of infection versus (for
504 h delay) lack of cure
w/o treatment
Kishor et al., 2016
aCFU, Colony-Forming Units; IP, Intraperitoneal; IV, Intravenous; MRSA, Methicillin-Resistant or Multi-drug Resistant Staphylococcus aureus; PFU, Plaque-Forming Units.
bTime between initial exposure to bacteria and initial exposure to phages. Shown per study are only those delays of longer than 24 h.
cDay indicated is post initial bacterial challenge.
d It is difficult to tell whether the phage administration was or was not made directly to the abscess.
ePhages were presumably delivered intravenously, though this is not explicitly stated.
fPhage additions were either 48- to 96-h prior to (96-h treatment) or 48- to 96-h post (240-h treatment) the cyclophosphamide-mediated induction of septicemia.
gThis was followed days later by cyclophosphamide IP injection to induce septicemia.
hP. aeruginosa saw similar drops without phage treatment though sooner with phage treatment; A. baumanni also saw substantial drops with phage treatment when assaying for colony
counts using selective media; mostly analogous though not identical and also more variable results were seen for S. aureus and P. aeruginosa with an otherwise equivalent pig model.
iBoth free and liposome-entrapped phages were administered in this study representing concentrations of 109 and 107 PFU/ml and multiplicities of infection of 1 and 0.01, respectively.
jNo difference in results was observed between control and 48-h delay in phage treatment w/o liposome entrapment. Note that 5-days post bacterial challenge is 3 and 2 days post 48
and 72-h phage treatment, respectively. The 72-h treatment also was reduced to zero CFU 7 days post bacterial challenge while the no-treatment control was reduced to 103 CFU/ml
at 7 days.
k3 and 6 weeks, respectively, though the 3-week treatment may in fact have actually begun on day 16.
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to “lysis from without” (Abedon, 2011) but which the authors
appear to be equating, incorrectly, with the concept of inundation
(Payne and Jansen, 2001). Inundation therapy generally is
assumed to involve bacteria killing though not necessarily also
phage replication nor even bacterial lysis.
A much more substantive concern is that these authors have,
in essence, made their reported treatment look too easy. This is
not a criticism of the results presented but instead stems from a
much more general question of just what constitutes a chronic
bacterial infection as typically treated clinically using phage
therapy. Thus, does this rabbit osteomyelitis model, impressive
as it appears, come close to actually modeling antibiotic-tolerant
chronic bacterial infections?
The authors indicate that chronic osteomyelitis is defined
by bone inflammation that has lasted for at least 6 weeks. By
contrast, by the time phage treatment has begun in the clinic,
chronic infections typically have persisted, often despite ongoing
antibiotic treatment, for up to many years, e.g., a median of 43
months as reported by Miedzybrodzki et al. (2012). Differences
therefore may exist between chronic osteomyelitis at 6 weeks and
that which phage therapists may encounter in the clinic, and
particularly so given that there have been delays in treatment
until after more conventional approaches have failed.
Drawing on the Kishor et al. (2016) study as well as others
presented in Table 1, I would like to suggest five criteria for
judging experimental animal infections as models for phage
therapy of chronic infections as encountered in the clinic. As the
first criterion should be assumed as a given, I start the list at zero:
0. Substantial delays, e.g., multiple days, weeks, or longer,
following bacterial challenge; minimally including
demonstration of some degree of infection stabilization
prior to the onset of phage treatment.
1. Equivalent degrees of site preparation as used clinically prior
to the onset of treatment, e.g., debridement in the case of
wound infections.
Generally these should be followed with at least two of the
following:
2. Demonstration, in most cases, of a lack of adequate
treatment success without multiple, temporally separated
phage applications over relatively long periods, i.e., if multiple
doses over weeks are required in the clinic to adequately
combat chronic infections then success using only a single
dose in the laboratory ought to be suspect.
3. Demonstration, in many cases, of development of biofilms
prior to treatment.
4. Demonstration of physiological development, by model
infections, of antibiotic tolerance.
The latter point in a sense is an operational definition since
chronic infections can become eligible for phage therapy due
to a failure to be effectively treated using antibiotics—failures
which are not necessarily consequences of genetically acquired
resistance and particularly as associated with biofilm formation.
Thus, chronic infection models for phage therapy in at least some
cases should be ones for which antibiotics, as normally employed,
have lost their ability to clear otherwise laboratory-sensitive
bacteria over the course of infection development.
In conclusion, with few quibbles, I want to stress that I am
delighted with Kishor et al.’s efforts. But, as with good science
generally, asmany questions are raised by their study as have been
answered.
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